
TVRD Stock Forecast & Price Target
TVRD Analyst Ratings
Bulls say
Tvardi Therapeutics's strong outlook is supported by promising developments in its product candidates TTI-101 and TTI-109, with ongoing Phase 2 trials showing potential improvements in safety and efficacy for treating idiopathic pulmonary fibrosis and hepatocellular carcinoma. The company’s robust anti-fibrotic strategy aims to address significant unmet medical needs, particularly in patients with high levels of fibrosis, raising expectations for TTI-109 due to its anticipated better tolerability compared to TTI-101. Early clinical data suggest that TTI-101 is performing well across various treatment lines, thereby enhancing its competitive positioning in the biopharmaceutical market.
Bears say
Tvardi Therapeutics Inc. is facing a negative outlook primarily due to the high competitive risk in its target markets, particularly in idiopathic pulmonary fibrosis and hepatocellular carcinoma, where established and emerging therapies may hinder its ability to achieve market share and viability. Additionally, there are concerns regarding financing, with expectations that the company will need to raise capital before reaching profitability, which could dilute existing shareholder value. The potential for clinical trial failures or unexpected safety signals further exacerbates these risks, as such setbacks could lead to asset impairments and diminished market confidence.
This aggregate rating is based on analysts' research of Cara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TVRD Analyst Forecast & Price Prediction
Start investing in TVRD
Order type
Buy in
Order amount
Est. shares
0 shares